SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James B. Barnes who wrote (324)1/13/1998 12:08:00 AM
From: Eduardo Canto  Read Replies (3) of 569
 
James, The product that was approved prior to Synvisc is called Hyalgan and it requires 5 injections. Hard to say without more info, but it seems like your mother is on an ACE inhibitor such as captopril, lisinopril, etc for her hypertension. She was probably given a nonsteroidal anti-inflamatory for her pain. In terms of Synvisc being not indicated for a patient that has their pain controlled by any medicine that is not otherwise threatening to the patient's health, the statement is incorrect. The indication as it appears on the box reads: "Synvisc is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy (in other words, no therapy) and simple analgesics, e.g. acetaminophen. (that's Tylenol)"

That was the one major victory that Biox brought to the field of hyaluronic acid for OA of the knee.

Best,
E.C.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News